This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Issues Alert on Amylin's Byetta

The Food and Drug Administration warned Tuesday that Amylin Pharmaceuticals (AMLN) Byetta, a type II diabetes drug, may be associated with cases of acute pancreatitis.

The agency issued an alert, saying that it's received 30 postmarketing reports of acute parncreatitis in patients taking Byetta, and that health care professionals should instruct patients taking the injection to seek prompt medical care if they experience symptoms such as unexplained persistent severe abdominal pain and possibly vomiting, and immediately discontinue the drug if the condition is suspected.

The FDA said Amylin has agreed to include information about acute pancreatitis in the precautions section of the product label. The San Diego-based company has a collaboration agreement with Eli Lilly (LLY - Get Report) and Alkermes (ALKS - Get Report) to develop a sustained release version of Byetta.

Amlyin, which reports third-quarter earnings Wednesday, was falling $2.44, or 4.9%, to $45.50 in recent trading Tuesday; Eli Lilly was down 73 cents, or 1.3%, at $57.22; and Alkermes fell 64 cents, or 3.6%, to $16.85.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALKS $40.26 -2.50%
LLY $75.73 -0.95%
TSLA $243.95 -1.50%
YHOO $36.39 -0.55%
AAPL $92.93 -2.00%


Chart of I:DJI
DOW 17,717.86 -112.90 -0.63%
S&P 500 2,068.87 -6.94 -0.33%
NASDAQ 4,788.6690 -16.6220 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs